Literature DB >> 11837909

Pertussis--United States, 1997-2000.

.   

Abstract

Pertussis was a major cause of morbidity and mortality among infants and children in the United States during the prevaccine era (i.e., before the mid-1940s). Following the introduction and widespread use of whole-cell pertussis vaccine combined with diphtheria and tetanus toxoids (DTP) among infants and children in the late 1940s, the incidence of reported pertussis declined to a historic low of 1,010 cases in 1976 (Figure 1). However, since the early 1980s, reported pertussis incidence has increased cyclically with peaks occurring every 3-4 years. In 1996, less reactogenic acellular pertussis vaccines (DTaP) were licensed and recommended for routine use among infants. This report summarizes national surveillance data for pertussis during 1997-2000 and assesses the effectiveness of pertussis vaccination in the United States during this period. The findings indicate that pertussis incidence continues to increase in infants too young to receive 3 doses of pertussis-containing vaccine and in adolescents and adults. Prevention efforts should be directed at maintaining high vaccination rates and managing pertussis cases and outbreaks.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11837909

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  49 in total

1.  Maternal immunity provides protection against pertussis in newborn piglets.

Authors:  Shokrollah Elahi; Rachelle M Buchanan; Lorne A Babiuk; Volker Gerdts
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

Review 2.  Reduced-antigen combined diphtheria-tetanus-acellular pertussis vaccine (Boostrix).

Authors:  Therese M Chapman; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

3.  Modelling the long-term dynamics of pre-vaccination pertussis.

Authors:  Ganna Rozhnova; Ana Nunes
Journal:  J R Soc Interface       Date:  2012-06-20       Impact factor: 4.118

4.  Establishment of diagnostic cutoff points for levels of serum antibodies to pertussis toxin, filamentous hemagglutinin, and fimbriae in adolescents and adults in the United States.

Authors:  Andrew L Baughman; Kristine M Bisgard; Kathryn M Edwards; Dalya Guris; Michael D Decker; Kathy Holland; Bruce D Meade; Freyja Lynn
Journal:  Clin Diagn Lab Immunol       Date:  2004-11

Review 5.  Pertussis vaccination for health care workers.

Authors:  Thomas J Sandora; Courtney A Gidengil; Grace M Lee
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

6.  Epidemiological characteristics of pertussis in Estonia, Lithuania, Romania, the Czech Republic, Poland and Turkey-1945 to 2005.

Authors:  Irja Lutsar; Ioana Anca; Mustafa Bakir; Vytautas Usonis; Roman Prymula; Nuran Salman; Pawel Grezesiowski; Michael Greenberg
Journal:  Eur J Pediatr       Date:  2008-07-05       Impact factor: 3.183

7.  Poor immune responses to a birth dose of diphtheria, tetanus, and acellular pertussis vaccine.

Authors:  Natasha B Halasa; Alice O'Shea; Jian R Shi; Bonnie J LaFleur; Kathryn M Edwards
Journal:  J Pediatr       Date:  2008-04-28       Impact factor: 4.406

Review 8.  Diagnosis and management of pertussis.

Authors:  Alberto E Tozzi; Lucia Pastore Celentano; Marta Luisa Ciofi degli Atti; Stefania Salmaso
Journal:  CMAJ       Date:  2005-02-15       Impact factor: 8.262

Review 9.  Prevention of pertussis through adult vaccination.

Authors:  Manika Suryadevara; Joseph B Domachowske
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

10.  Bordetella species are distinguished by patterns of substantial gene loss and host adaptation.

Authors:  C A Cummings; M M Brinig; P W Lepp; S van de Pas; D A Relman
Journal:  J Bacteriol       Date:  2004-03       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.